HCA Healthcare (HCA): A Target Cut, But Execution Still Gets Credit
π Deutsche Bank reduced its price target for HCA Healthcare from $558 to $540.
π Despite the downgrade, Deutsche Bank maintains a Buy rating on the stock.
π€ The adjustment reflects concerns over a 7.3% cut in operating profit for 2026.
βοΈ Management still receives credit for strong execution and effective cost management.
π HCA Healthcare currently carries an average analyst price target of $516.55.
π₯ The stock has fallen to an overweight rating consensus from the analyst community.
π This news was published on April 28, 2026, amidst broader market volatility.
- Deutsche Bank maintains a Buy rating on HCA Healthcare despite cutting the price target, signaling confidence in the company's long-term fundamentals.
- The stock still holds an average analyst rating of overweight with a mean price target of $516.55, indicating continued institutional interest.
- Deutsche Bank adjusted HCA Healthcare's price target downward to $540 from $558, indicating negative analyst sentiment despite maintaining a buy rating.
- The stock is currently trading at a -0.31% daily decline, reflecting immediate market pressure on the healthcare sector.